User:Mr. Ibrahem/Sotrovimab

Sotrovimab, sold under the brand name Xevudy, is a medication which was used to treat COVID-19 in people who do not need supplemental oxygen but are a high risk of getting severe disease. In this group it decreased the need for hospitalization. It; however, does not appear effective for Omicron BA.2 subvariant and is not recommended in regions were this makes up more than half of cases. It is given by gradual injection into a vein.

Common side effects include allergic reactions including anaphylaxis. Anaphylaxis occurs in about 1 in 2,000 people. Safety in pregnancy or breastfeeding is unclear. It is a monoclonal antibody which attaches to the spike protein of SARS-CoV-2 making the virus unable to enter the body’s cells.

Sotrovimab was approved for medical use in Europe in 2021. It has Emergency Use Authorization (EUA) in the United States as of 2021. In the United States it costs 2,100 USD per dose, with this amount paid by the the United States government.